Evidence mapPaperPMID 33518159Full record

ReviewGastroenterology clinics of North America2021

Precision Medicine and Obesity.

Maria Daniela Hurtado A, Andres Acosta

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Gastroenterology clinics of North America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06132477 (Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric), which is not on this map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06132477 phase4recruitingstarted 2024, after this paper: background citation

Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric

Ran2024Enrolled150Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Hypertension, Metabolic Syndrome, Morbid ObesityArmsGLP-1 receptor agonist
Open the trial in the graph
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 45 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Adult obesity treatment and prevention: A trans-agency commentary on the research landscape, gaps, and future opportunities.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2024
    Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Assessment of obesity.Clinical medicine (London, England) · 2023
    Article
  18. Review
  19. Review
  20. 5-HTNutrients · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Maria Daniela Hurtado ADivision of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic Health System, 700 West Ave South, La Crosse, WI 54601, USA; Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA. Electronic address: https://twitter.com/MDanielaHurtado.
Andres AcostaDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA. Electronic address: Acosta.andres@mayo.edu.
Mayo Clinic · USMayo Clinic Health System · US

Funding

NIDDK NIH HHS K23 DK114460
6 · The paper itself

Abstract

The highly variable response to obesity therapies justifies the search for treatment strategies that are best suited to individual patients to enhance their effectiveness and tolerability via precision medicine. Precision medicine development in recent years has been driven by the emergence of powerful methods to characterize patients ("omic" assays). Current available information has revealed that there are numerous intermediary processes that contribute to obesity and have provided a framework for partially comprehending the mechanisms behind the heterogeneity of obesity and its clinical consequences. Some of these processes have or are currently being targeted to individualize obesity therapy with some success.

Indexed as

NutrigenomicsPrecision MedicineHumansObesityNutrigenomicsObesityPersonalized nutritionPhenotypePrecision medicine

Identifiers

PMID33518159
PMCPMC7863578
OpenAlexW3119880462

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.